The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic.

A. Barker,C. Compton,G. Poste
DOI: https://doi.org/10.2217/bmm.14.52
2014-09-16
Biomarkers in Medicine
Abstract:Biomarker development is rarely successful Realizing the much vaunted promise of precision (personalized) medicine is linked inextricably to the availability of robust and clinically relevant biomarkers. Given their importance in supporting more informed treatment decisions, enabling earlier diagnosis and driving the development of molecular based therapies, biomarkers arguably represent the greatest potential value in biomedicine today. In short, biomarkers are the ‘holy grail’ of precision medicine. The BCR–ABL and HER-2 proteins are prototypic examples of the clinical utility of biomarkers in cancer that have transformed the classification of lymphocytic leukemia and HER-2 positive breast cancer, respectively, and driven more rational treatment decisions. Unfortunately, these remain rare examples. The potential of biomarkers to revolutionize the detection, diagnosis and clinical management of cancer remains largely unrealized, with fewer than 100 biomarkers approved by regulatory agencies as companion diagnostics for molecular profiling to guide treatment selection [1]. There is a staggering asymmetry between the several 100,000 publications describing candidate biomarkers and the mere fraction of 1% of these that ever progress to clinical practice [2]. The systematic failure in biomarker R&D is further illustrated by the fact that the US FDA has approved less than one protein biomarker per year since the mid 1990s [3]. The burden of these failures, which come at incalculable cost in wasted investment, intellectual resources and patient samples, are incompatible with charting a reliable intellectual foundation for molecular medicine and improved patient care.
What problem does this paper attempt to address?